CJC-1295 + Ipamorelin

CJC-1295 functions by binding to and activating the GHRH receptor (GHRHR), a Gs protein-coupled receptor expressed on anterior pituitary somatotrophs. This interaction stimulates adenylyl cyclase, elevating intracellular cyclic AMP (cAMP) concentrations, which in turn activates protein kinase A (PKA) and promotes calcium influx via voltage-gated channels. The downstream effect in experimental models is the stimulation of growth hormone gene transcription and pulsatile GH secretion. The DAC modification in CJC-1295 extends its half-life in biological matrices by enabling reversible covalent binding to serum albumin, making it a useful tool for studies requiring sustained GHRH receptor engagement without frequent re-dosing in animal protocols.

Ipamorelin operates through a mechanistically independent pathway, selectively agonizing the growth hormone secretagogue receptor type 1a (GHSR-1a), a Gq/11-coupled GPCR. GHSR-1a activation triggers phospholipase C (PLC)-mediated hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP₂), generating inositol trisphosphate (IP₃) and diacylglycerol (DAG), which mobilize intracellular calcium stores and activate protein kinase C (PKC). Notably, Ipamorelin exhibits high selectivity for GHSR-1a relative to other secretagogue receptors, producing minimal off-target effects on cortisol or prolactin release in preclinical models—a property that makes it a well-characterized research tool for isolating GH secretagogue activity. When CJC-1295 and Ipamorelin are used in combination in experimental settings, the cAMP and IP₃/DAG pathways converge at the level of intracellular calcium elevation, producing an amplified and more physiologically representative GH release profile than either peptide alone.

CJC-1295 and Ipamorelin are employed across a range of preclinical and in vitro research contexts, particularly in studies requiring modulation of the GH/IGF-1 axis. The following represent documented research application areas for this peptide combination:

• Pituitary cell signaling studies: Investigation of cAMP and IP₃ second messenger pathway crosstalk in primary pituitary somatotroph cultures or GH3 cell lines following dual GHRHR and GHSR-1a activation.
• GH secretion kinetics: Characterization of pulsatile GH release profiles in rodent models, including amplitude, frequency, and duration of secretory bursts under combinatorial peptide stimulation.
• IGF-1 axis modulation: Preclinical assessment of hepatic IGF-1 mRNA expression and circulating IGF-1 levels following administration of CJC-1295 and Ipamorelin in rodent cohorts.
• Receptor selectivity profiling: Comparative binding and functional assays to evaluate GHSR-1a vs. GHRHR selectivity, off-target receptor interactions, and signal bias using radioligand displacement or BRET-based approaches.
• Metabolic parameter research: Examination of body composition endpoints (lean mass, adipose tissue distribution) and metabolic biomarkers in diet-induced or genetic animal models within IACUC-approved protocols.
• Peptide half-life and pharmacokinetic modeling: In vitro plasma stability assays and in vivo PK studies assessing the influence of DAC albumin binding on the tissue distribution and elimination of CJC-1295 relative to unmodified GHRH analogues.